12results about "Cell differentiation" patented technology

To provide methods of lineage specific differentiation of pluripotent stem cells, including induced pluripotent stem cells, into floor plate midbrain progenitor cells, determined dopamine (DA) neuron progenitor cells, and / or DA neurons.SOLUTION: Provided is a method of differentiating neural cells, the method comprising: (a) performing a first incubation comprising culturing pluripotent stem cells in a non-adherent culture vessel under conditions to produce a cellular spheroid; and (b) performing a second incubation comprising culturing cells of the spheroid in a substrate-coated culture vessel under conditions to neurally differentiate the cells.SELECTED DRAWING: Figure 1

The present invention relates to a method for producing an in vitro model of a human neurological disease. Furthermore, the invention relates to the in vitro model produced according to the method disclosed herein. The invention also relates to the use of the in vitro model in drug testing. In addition, the invention relates to methods for testing the efficacy of drugs in preventing, delaying, and alleviating a human neurological disease.

A method is provided for generating human forebrain neural progenitor cells and mature forebrain neurons from human pluripotent stem cells using a chemically defined medium. The method allows for the initial generation of OTX2+ FEZF2+ SIX3+ forebrain neural stem cells, which can then be cultured to generate NKX2-1+ ventral forebrain neural stem cells and subsequently ASCL1+ medial ganglia primitive neural progenitor cells (MGE-NPCs). The MGE-NPCs are further differentiated into immature neurons and mature GABAergic interneurons. Culture media, isolated cell populations, and kits are also provided.

The present invention relates to a Crystalline Form A of a compound of Chemical Formula 1 having physically and chemically outstanding characteristics compared to amorphous forms and other crystalline forms of the compound of Chemical Formula 1. Crystalline Form A of the compound of Chemical Formula 1 according to the present invention, compared to amorphous forms or other crystalline forms, does not denature even at prolonged exposure to harsh conditions, has low water sorption, is advantageous for formulation as the crystalline form does not change even under pressure or when pulverized, and the crystalline form itself has excellent stability, being useful for storage for extended periods.

A first aspect of the invention relates to a method for preparing a three dimensional blood vessel organoid. In a second aspect, the invention is directed to three dimensional human blood vessel organoids obtained or obtainable from the method of the first aspect of the invention. A third aspect of the invention is related to the three dimensional human blood vessel organoids for use in (in vitro) drug screening and / or (in vitro) drug testing; and / or for use in (in vitro) toxicity analysis; and / or for use in (in vitro) bioengineering; and / or for (in vitro) transplant preparation.

Provided are: a method for culturing animal cells, wherein animal cells are cultured in the presence of an iron ion carrier such as hinokitiol; and a technique related thereto.

The present disclosure provides methods of lineage specific differentiation of pluripotent stem cells, including induced pluripotent stem cells, into floor plate midbrain progenitor cells, determined dopamine (DA) neuron progenitor cells, and / or DA neurons. Also provided are compositions and uses thereof, such as for treating neurodegenerative diseases and conditions, including Parkinson's disease.

Provided is a method for efficiently manufacturing high-purity peripheral nerve cells from undifferentiated cells. The method for manufacturing peripheral nerve cells from undifferentiated cells having an ability to differentiate into peripheral nerve cells includes the following steps (a) and (b): (a) culturing undifferentiated cells having an ability to differentiate into peripheral nerve cells to induce differentiation into neural progenitor cells without detaching a grown colony from a culture vessel; and (b) detaching the neural progenitor cells produced in the step (a) from the culture vessel, then seeding the cells at a seeding density of 2×105 to 6×105 cells / cm2 to a culture vessel, and culturing the cells for 14 to 42 days.

Methods, compositions and cells are provided that identify and isolate a population of adult non-embryonic progenitor cells having multilineage potential, physical diameters of about 2 μm to about 8 μm in size or about 4 μm to about 6 μm, and expressing at least one of the stem cell associated genes among Oct-4, KLF-4, Nanog, Sox-2, Rex-1, GDF-3 or Stella. Methods are also provided that identify and isolate populations, which are subsets or subpopulations of progenitor adult stem cells within the population of the adult stem cells which is a heterogeneous population, the methods including contacting the adult stem cells with a ligand specific for at least one of: CD99, tetraspan, ICAM4, full-length MUC1, and truncated MUC1 receptor, in which a presence of a surface protein on the cells that bind to the ligand identifies the population which is the subset of the differentiated progenitor adult stem cells.

The present disclosure relates to compositions, constructs and vectors for reprogramming cells into plasmacytoid dendritic cells or interferon type I-producing cells, methods and uses thereof. The present disclosure relates to the development of methods for making plasmacytoid dendritic cells or interferon type I-producing cells that promote antiviral and anti-tumoral immune responses from differentiated, multipotent or pluripotent stem cells by introducing and expressing isolated / synthetic transcription factors. More particularly, the disclosure provides methods for obtain plasmacytoid dendritic cells or interferon type I-producing cells by direct cellular reprogramming with the surprisingly use of combinations of specific transcription factors.

The present disclosure provides methods of lineage specific differentiation of pluripotent stem cells, including induced pluripotent stem cells, into floor plate midbrain progenitor cells, determined dopamine (DA) neuron progenitor cells, and / or DA neurons. Also provided are compositions and uses thereof, such as for treating neurodegenerative diseases and conditions, including Parkinson's disease.

Methods, compositions and cells are provided that identify and isolate a population of adult non-embryonic progenitor cells having multilineage potential, physical diameters of about 2 μm to about 8 μm in size or about 4 μm to about 6 μm, and expressing at least one of the stem cell associated genes among Oct-4, KLF-4, Nanog, Sox-2, Rex-1, GDF-3 or Stella. Methods are also provided that identify and isolate populations, which are subsets or subpopulations of progenitor adult stem cells within the population of the adult stem cells which is a heterogeneous population, the methods including contacting the adult stem cells with a ligand specific for at least one of: CD99, tetraspan, ICAM4, full-length MUC1, and truncated MUC1 receptor, in which a presence of a surface protein on the cells that bind to the ligand identifies the population which is the subset of the differentiated progenitor adult stem cells.